

Table1. Neuropsychological assessment in anti-LGI1 encephalitis case with teratoma

Scale	Time since admission				
	Day 6	Day 32	Month 3	Month 4	Month 5
<b>MMSE</b>					
Total	13	19	26	24	27
Orientation	5	7	10	9	9
Registration	2	3	3	3	3
Attention and Calculation	2	1	1	1	5
Recall	0	0	3	2	1
Language	4	8	9	9	9
<b>MoCA</b>					
Total	N/A	20	24	28	29
Visuospatial and Executive function	N/A	4	5	5	5
Animal naming	N/A	3	3	3	3
Attention	N/A	4	4	4	6
Language	N/A	3	3	3	3
Abstraction	N/A	2	1	2	2
Delayed recall	N/A	0	2	5	4
Orientation	N/A	4	6	6	6
<b>HAMA</b>			8	2	4
<b>HAMD</b>			12	0	3

N/A, MoCA was not performed because the patient was too irritated.

MMSE, Mini-Mental State Examination; MoCA, Montreal cognitive assessment; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; BI, Barthel Index; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive section.

Table 2. Clinical characteristics of anti-LGI1 encephalitis cases with and without teratoma and anti-NMDAR encephalitis with teratoma

Clinical characteristics	Anti-LGI1 encephalitis without teratoma (N (%))	Anti-NMDAR encephalitis with teratoma (N (%))	Anti-LGI1 encephalitis with teratoma
Total Number	9	3	1
Female	3/9 (33%)	3/3 (100%)	Yes
Age at onset (y, mean±SD (range))	47.3±15.6 (19-67)	27.7±6.6 (19-35)	48
Disease onset	9	3	
Acute	6 (67%)	3 (100%)	
Sub-acute	3 (33%)	0	
Chronic	0	0	Yes
Clinical symptoms	9	3	
Symptoms at onset	9	3	
Behavioral disorders	2 (22%)	1 (33%)	
FBDS	2 (22%)	0	
Cognitive impairment	1 (11%)	0	
Behavioral disorders+Cognitive impairment	1 (11%)	0	
RBD	1 (11%)	0	
Dizziness	1 (11%)	0	
Sleep disorder	0	1 (33%)	
Fever + headache	0	1 (33%)	
Mood disorder	0	0	Yes
Mood disorder + FBDS	1 (11%)	0	
Symptoms through entire disease course	9	3	
Seizures	8 (89%)	2 (67%)	

Generalized convulsions	4/8 (50%)	2/2 (100%)	
FBDS	3/8 (38%)	0	
Focal seizures	1/8 (13%)	0	
Status epilepticus	0	0	Yes
Cognitive impairment	6 (67%)	2 (67%)	Yes
Hallucinations	3 (33%)	3 (100%)	Yes
Sleep disorder	6 (67%)	3 (100%)	Yes
Insomnia	3/6 (50%)	1/3 (33%)	
RBD	2/6 (33%)	0	
Drowsiness	1/6 (17%)	2/3 (67%)	Yes
Ancillary test results			
Evidence of tumor	0	3 (100%)	Yes
Hyponatremia	7 (78%)	0	Yes
CSF	7 (78%)	3 (100%)	
Cell count < 8 cells/mL	7/7 (100%)	1/3 (33%)	Yes
Protein ≤0.58g/L	7/7 (100%)	3/3 (100%)	Yes
Positive antibody immunoassay	9 (100%)	3 (100%)	
Serum	2/9 (22%)	1 (33%)	
CSF	2/9 (22%)	0	
Serum +CSF	5/9 (56%)	2 (67%)	Yes
EEG	6 (67%)	3 (100%)	
Background slowing	3/6 (50%)	0	Yes
Background slowing + epileptic discharges	1/6 (17%)	2 (67%)	
Normal	2/6 (33%)	1 (33%)	
MRI	9 (100%)	3 (100%)	
Hippocampal lesion	8 (89%)	1 (33%)	
Bilateral	4/8 (50%)	1/1 (100%)	Yes

Unilateral	4/8 (50%)	0	
Meningeal enhancement	0	1 (33%)	
Normal	1 (11%)	1 (33%)	
Cognitive function evaluation results	6 (67%)	2/3 (67%)	
MMSE<=24	3/6 (50%)	1/2 (50%)	Yes
MOCA<=26	1/6 (17%)	1/2 (50%)	Yes
Normal	2/6 (33%)	0	
Pharmacological Therapy	9 (100%)	3 (100%)	
MPT	5 (56%)	0	
MPT+IVIG	1 (11%)	1 (33%)	Yes *
MPT+ immunosuppressant	2 (22%)	0	
MPT+IVIG+ immunosuppressant	0	1 (33%)	
MPT+IVIG+ plasma exchange	0	1 (33%)	
MPT+immunosuppressant+plasma exchange	1 (11%)	0	
Follow-up	8 (89%)	3 (100%)	
mRS evaluation	8 (89%)	3 (100%)	
<=2	6/8 (75%)	3 (100%)	Yes
>2	2/8 (25%)	0	
Residual symptoms or death	8 (89%)	3 (100%)	
No symptom	3/8 (38%)	2/3 (67%)	
Short-term memory impairment	2/8 (25%)	1/3 (33%)	Yes
FBDS	1/8 (13%)	0	
Death	2/8 (25%)	0	

Yes means the LGI1 encephalitis patient with teratoma had the symptom.

LGI1, leucine-rich glioma-inactivated 1; NMDAR: N-methyl-D-aspartate receptor; FBDS, faciobrachial dystonic seizures; RBD: rapidly eye movement behavior disorder; CSF, cerebrospinal fluid; EEG, electroencephalography; MRI: magnetic resonance imaging; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; MPT: methylprednisolone pulse therapy; IVIG: intravenous immunoglobulin; mRS: modified Rankin Scale.

\*reduced methylprednisolone dose